Key result
Heart transplantation represents an excellent option for patients with end-stage hypertrophic cardiomyopathy, providing a 1-year survival rate of 84% and a 10-year survival rate of 59%.
Heart transplantation is a viable and life-saving option for the minority of hypertrophic cardiomyopathy patients who progress to end-stage heart failure, offering good long-term survival despite specific challenges like pulmonary hypertension.
Supports transplantation consideration in end-stage HCM; leaves open prospective studies to refine selection and timing.
[first paragraph of article]Hypertrophic cardiomyopathy has a broad spectrum of clinical presentations, from asymptomatic to patients with advanced heart failure and sudden death. Treatment options are limited, especially in non-obstructive forms. A minority of patients (around 3.5%) can progress to an end-stage state, characterized by systolic dysfunction and restrictive ventricular filling, related to extensive fibrotic replacement and chamber remodeling. In these cases, life expectancy is significantly reduced: a mean 3-year survival time has been reported.
No takes yet. Share an insight, caveat, or question.
Torres et al. (2018) conducted a review in Hypertrophic cardiomyopathy. Heart transplantation was evaluated. Heart transplantation represents an excellent option for patients with end-stage hypertrophic cardiomyopathy, providing a 1-year survival rate of 84% and a 10-year survival rate of 59%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Heart transplantationMore from Global Cardiology Science and Practice